Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B P Monia

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Journal of Medicinal Chemistry|December 20, 1996
2'-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotidesR H Griffey, B P Monia, L L Cummins, et al.
Diabetologia|December 31, 2010
Knockdown of the gene encoding Drosophila tribbles homologue 3 (Trib3) improves insulin sensitivity through peroxisome proliferator-activated receptor-γ (PPAR-γ) activation in a rat model of insulin resistanceD Weismann, D M Erion, I Ignatova-Todorava, et al.
Science Advances|October 23, 2018
Targeted delivery of antisense oligonucleotides to pancreatic β-cellsC Ämmälä, W J Drury, L Knerr, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Journal of Medicinal Chemistry|December 20, 1996
2'-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotidesR H Griffey, B P Monia, L L Cummins, et al.
Diabetologia|December 31, 2010
Knockdown of the gene encoding Drosophila tribbles homologue 3 (Trib3) improves insulin sensitivity through peroxisome proliferator-activated receptor-γ (PPAR-γ) activation in a rat model of insulin resistanceD Weismann, D M Erion, I Ignatova-Todorava, et al.
Science Advances|October 23, 2018
Targeted delivery of antisense oligonucleotides to pancreatic β-cellsC Ämmälä, W J Drury, L Knerr, et al.
Pageof 8